Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus

BACKGROUND: Intravenous belimumab 10 mg/kg every 4 weeks is indicated in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard systemic lupus erythematosus care. Subcutaneous 200-mg weekly administration, which may prove more convenient for patients and improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Struemper, Herbert, Thapar, Mita, Roth, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973992/
https://www.ncbi.nlm.nih.gov/pubmed/28887801
http://dx.doi.org/10.1007/s40262-017-0586-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973992/
https://www.ncbi.nlm.nih.gov/pubmed/28887801
http://dx.doi.org/10.1007/s40262-017-0586-5

Ejemplares similares